Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|February 22, 2019
Stage IIIA Unresectable NSCLC After Chemoradiotherapy
Stage IIIA Unresectable NSCLC After Chemoradiotherapy
Advertisement
Case: A 52-Year-Old Male With Stage IIIA NSCLC
Initial presentation
- A 52-year-old man presented with a 15-lb weight loss and worsening dyspnea
- PMH: HTN
- SH: Computer programmer; Smoked a pack/day for 30 years; Quit smoking 2 years ago; Married with 4 kids
- PE: Unremarkable
Clinical workup
- Imaging:
- Initial CT showed a 5-cm left upper lobe mass with aortopulmonary window and left paratracheal adenopathy measuring up to 2.5 cm
- Subsequent PET scan showed activity in the left upper lobe mass and all nodal areas
- No extrathoracic disease was identified
- MRI showed no brain metastases
- Mediastinal sampling: EBUS was performed and documented squamous carcinoma in the left paratracheal lymph nodes
- Staging: T2N2M0
- ECOG PS 1
- Multidisciplinary tumor board deemed his tumor unresectable due to multistation N2 disease
Treatment
- Concurrent cisplatin/etoposide with external-beam radiotherapy
- Repeat CT 4 weeks after completion of concurrent chemoradiotherapy showed a PR with no new sites of disease
Advertisement
Related to this article
The NDA was completed for first-line zipalertinib plus platinum chemotherapy in EGFR exon 20 insertion NSCLC, based on phase 3 REZILIENT3 data showing improved PFS.
Telisotuzumab adizutecan showed promising survival in pretreated nonsquamous NSCLC, with the most benefit in EGFR wild-type tumors with high c-Met levels.
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
New ACS Guidelines Push for Earlier Prostate Cancer Screening
4
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
5